If you have the Genetic Targets – we may just have the right technology to knock them down

Tech Image

The versatility of AUM’s next generation RNA silencing and regulation technology can potentially allow us to target any disease indication as long as it has RNA based genetic link. This can be mRNA, micro RNA or a long non coding RNA. We are interested in all therapeutic areas (not limited to the following).

Hematology/Oncology – Cancer
CNS (e.g. Alzheimer)
Metabolic
Kidney/Liver
IBD
GI
Auto-Immune/inflammatory (e.g. Psoriasis, Rheumatoid arthritis)
HIV and other viral indications – Infectious diseases
Cardiovascular
Orphan diseases (e.g. Duchenne muscular dystrophy and others)

We are always looking for collaborations or strategic alliances with academic labs, research organizations, non-profit organizations or biotech/pharma companies. Click here to learn more.